Biodeal Pharmaceuticals Raises ₹385 Crore From RMB Capitalworks For Expansion And R&D
Mumbai, August 10, 2026: Biodeal Pharmaceuticals on Monday announced a Rs 385 crore investment from RMB Capitalworks for business expansion and research and development activities. This is the first equity raise by the two-decade-old Biodeal, a contract development and manufacturing organisation. RMB, a unit of South African lender FirstRand Bank, will get an undisclosed stake in the company.…
Mumbai, August 10, 2026: The contract development and manufacturing firm Biodeal Pharmaceuticals has announced an equity raise of Rs 385 crore from RMB Capitalworks, a unit of South African lender FirstRand Bank. This marks the first equity raise for the two-decade-old company. RMB Capitalworks will acquire an undisclosed stake in Biodeal.
Anurag Kumar, Chairman and Managing Director of Biodeal, stated that the company intends to expand into new markets and conduct research and development for novel molecules. RMB Capitalworks Managing Partner Anshuman Malur commented that healthcare is a primary focus for the investment platform, and Biodeal's dedicated leadership makes it an attractive prospect for rapid expansion.
In FY26, Biodeal generated revenue of Rs 325 crore and an operating profit margin of 20%. The company aims to double its revenue to Rs 500 crore in FY27 and aims to reach Rs 1,200 crore by FY30, driven by new product launches and the financial support from the RMB investment.
Written by urgent.news from Free Press Journal's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
